Integrated Analysis of Hepatic MiRNA and MRNA Expression Profiles in the Spontaneous Reversal Process of Liver Fibrosis

Overview

Journal Front Genet

Date 2021 Aug 9

PMID 34367261

Citations 2

Authors

Yang Tai

Chong Zhao

Tian Lan

Linhao Zhang

Yang Xiao

Huan Tong

Rui Liu

Chengwei Tang

Jinhang Gao

Affiliations

Soon will be listed here.

Abstract

Liver fibrosis results from the imbalance between extracellular matrix (ECM) production and degradation, which is a common pathological consequence of various chronic liver diseases. Although many miRNAs have been reported in liver fibrosis progression, miRNA-mRNA interactions in its reversal process remain to be elucidated. In the current study, we performed an integrated analysis of miRNA and mRNA expression profiles in the mouse model with the spontaneous reversal potency of liver fibrosis. A total of 102 miRNA and 2,845 mRNAs showed significant differential expression in reversal mice compared to fibrotic mice. Moreover, 3,769 putative negatively correlated miRNA-mRNA pairs were revealed to be potentially implicated in the biological function regulation of small molecule metabolism and ECM organization. By integrating miRNA-mRNA regulatory networks, mmu-miR-1843a-5p, mmu-miR-193a-5p, mmu-miR-194-2-3p, and mmu-miR-30c-2-3p were identified as lysyl oxidases-specific miRNAs that were correlated with fibrosis reversal. Our results provided potential candidate targets for the treatment of liver fibrosis.

Citing Articles

CircNSD1 promotes cardiac fibrosis through targeting the miR-429-3p/SULF1/Wnt/β-catenin signaling pathway.

Ji D, Jin S, Jiang Y, Xu F, Fan S, Zhao Y Acta Pharmacol Sin. 2024; 45(10):2092-2106.

PMID: 38760544 PMC: 11420342. DOI: 10.1038/s41401-024-01296-7.

miR-488-5p mitigates hepatic stellate cell activation and hepatic fibrosis via suppressing TET3 expression.

Qiu J, Wu S, Wang P, Zhou Y, Wang Z, Sun Y Hepatol Int. 2022; 17(2):463-475.

PMID: 36001230 PMC: 10119239. DOI: 10.1007/s12072-022-10404-w.

References

Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S . Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol. 2012; 58(2):234-9. DOI: 10.1016/j.jhep.2012.10.015. View

Langmead B, Trapnell C, Pop M, Salzberg S . Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009; 10(3):R25. PMC: 2690996. DOI: 10.1186/gb-2009-10-3-r25. View

Chen C, Chen H, Zhang Y, Thomas H, Frank M, He Y . TBtools: An Integrative Toolkit Developed for Interactive Analyses of Big Biological Data. Mol Plant. 2020; 13(8):1194-1202. DOI: 10.1016/j.molp.2020.06.009. View

Yang X, Ma L, Wei R, Ye T, Zhou J, Wen M . Twist1-induced miR-199a-3p promotes liver fibrosis by suppressing caveolin-2 and activating TGF-β pathway. Signal Transduct Target Ther. 2020; 5(1):75. PMC: 7272438. DOI: 10.1038/s41392-020-0169-z. View

Karsdal M, Manon-Jensen T, Genovese F, Kristensen J, Nielsen M, Sand J . Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2015; 308(10):G807-30. PMC: 4437019. DOI: 10.1152/ajpgi.00447.2014. View

Van Keuren-Jensen K, Malenica I, Courtright A, Ghaffari L, Starr A, Metpally R . microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C. Liver Int. 2015; 36(3):334-43. PMC: 5049661. DOI: 10.1111/liv.12919. View

Ikenaga N, Peng Z, Vaid K, Liu S, Yoshida S, Sverdlov D . Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut. 2017; 66(9):1697-1708. PMC: 5561383. DOI: 10.1136/gutjnl-2016-312473. View

Kisseleva T, Brenner D . Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2020; 18(3):151-166. DOI: 10.1038/s41575-020-00372-7. View

Zhao W, Yang A, Chen W, Wang P, Liu T, Cong M . Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(4 Pt A):1129-1137. DOI: 10.1016/j.bbadis.2018.01.019. View

10.

Kweon Y, Goodman Z, Dienstag J, Schiff E, Brown N, Burchardt E . Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001; 35(6):749-55. DOI: 10.1016/s0168-8278(01)00218-5. View

11.

Tsuchida T, Lee Y, Fujiwara N, Ybanez M, Allen B, Martins S . A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018; 69(2):385-395. PMC: 6054570. DOI: 10.1016/j.jhep.2018.03.011. View

12.

Ellis E, Mann D . Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012; 56(5):1171-1180. DOI: 10.1016/j.jhep.2011.09.024. View

13.

Han X, Wu Y, Yang Q, Cao G . Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis. Pharmacol Ther. 2020; 222:107791. DOI: 10.1016/j.pharmthera.2020.107791. View

14.

Wang L, Feng Y, Xie X, Wu H, Su X, Qi J . Neuropilin-1 aggravates liver cirrhosis by promoting angiogenesis via VEGFR2-dependent PI3K/Akt pathway in hepatic sinusoidal endothelial cells. EBioMedicine. 2019; 43:525-536. PMC: 6558257. DOI: 10.1016/j.ebiom.2019.04.050. View

15.

Kim D, Paggi J, Park C, Bennett C, Salzberg S . Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019; 37(8):907-915. PMC: 7605509. DOI: 10.1038/s41587-019-0201-4. View

16.

Wang X, He Y, Mackowiak B, Gao B . MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2020; 70(4):784-795. DOI: 10.1136/gutjnl-2020-322526. View

17.

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K . Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021; 74(4):1809-1824. DOI: 10.1002/hep.31843. View

18.

ISHAK K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F . Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6):696-9. DOI: 10.1016/0168-8278(95)80226-6. View

19.

Wei S, Wang Q, Zhou H, Qiu J, Li C, Shi C . miR-455-3p Alleviates Hepatic Stellate Cell Activation and Liver Fibrosis by Suppressing HSF1 Expression. Mol Ther Nucleic Acids. 2019; 16:758-769. PMC: 6539335. DOI: 10.1016/j.omtn.2019.05.001. View

20.

He C, Shu B, Zhou Y, Zhang R, Yang X . The miR-139-5p/peripheral myelin protein 22 axis modulates TGF-β-induced hepatic stellate cell activation and CCl-induced hepatic fibrosis in mice. Life Sci. 2021; 276:119294. DOI: 10.1016/j.lfs.2021.119294. View